Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iparomlimab and Tuvonralimab in Locally Advanced Nasopharyngeal Carcinoma
NCT07135804Phase 2Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Nanchang University
- Start
- Sep 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Fc-Fusion Proteins
01
Overview
A Phase 2 trial of iparomlimab + tuvonralimab in nasopharyngeal carcinoma (NPC), sponsored by The Second Affiliated Hospital of Nanchang University. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
iparomlimab + tuvonralimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07135804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135804.